Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase

Thrombosis and Haemostasis

Volumn 76, Issue 3, 1996, Pages 339-343

  Galvani, Marcello ^a,c   Abendschein, Dana R ^b   Ferrini, Donatella ^a   Ottani, Filippo ^a   Rusticali, Franco ^a   Eisenberg, Paul R ^b  

^a Divisione di Cardiologia   (Italy)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fondazione Cardiologica Sacco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MM; FIBRIN DEGRADATION PRODUCT; FIBRINOPEPTIDE A; HEPARIN; MONOCLONAL ANTIBODY; STREPTOKINASE; THROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

EID: 0029830461     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650580     Document Type: Article

References (21)

1. Ridker PM, Hebert PR, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341: 1574-7.
2. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A: Evidence for continued thrombosis despite intensive fibrinolysis. J Am Coll Cardiol 1987; 10: 527-9.
3. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994; 24: 1445-552.
4. The GUSTO angiographic investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
5. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
6. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-20.
7. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-56.
8. Hart R, Bate I, Dinh D, et al. The detection of D-dimer in plasma by enzyme immunoassay: Improved discrimination is obtained with a more specific signal antibody. Blood Coag Fibrinol 1994; 5: 227-32.
9. Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 1990; 82: 1159-68.
10. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogenes. Acta Haematol (Basel) 1957; 17: 237-46.
11. Abendschein DR, Ellis AK, Eisenberg PR, Klocke FJ, Sobel BE, Jaffe AS. Prompt detection of coronary recanalization by analysis of rates of change of concentrations of macromolecular markers in plasma. Cor Art Dis 1991; 2: 201-12.
12. Lawler CW, Bovill EG, Stump DC, Collen D, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen Bβ peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 1990; 76: 1341-8.
13. Salvioni A, Marenzi GC, Agostoni P, Grazi S, Guazzi MD. Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase. Eur Heart J 1994; 15: 654-9.
14. Eisenberg PR, Galvani M, Ferrini D, Ottani F, Rusticali F, Abendschein D. Importance of assay specificity in interpretation of cross-linked fibrin degradation in patients treated with fibrinolytic agents. Fibrinolysis 1994; 8: 4 (A).
15. Francis CW, Doughney KB, Brenner B, Klingbiel K, Marder VJ. Increased reactivity of plasma after fibrinolytic activation in an anti-DD ELISA system: Role of soluble crosslinked fibrin polymers. Circulation 1989; 79: 666-73.
16. Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-40.
17. Haskel EJ, Eisenberg PR, Abendschein DR. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood. Blood Coag Fibrinol 1993; 4: 7-13.
18. Weitz JI, Kuint J, Leslie B, Hirsch J. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis of fibrinogenolysis. Thromb Haemost 1991; 65: 541-4.
19. ISIS-3 (Third International Study on Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
20. Gruppo italiano per lo studio della sopravvivenza nell' infarto miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
21. TIMI-9 Investigators (presented at the American Heart Association Sessions, Anaheim, CA, November 1995).